Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. APLT
stocks logo

APLT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.130
-139.39%
--
--
-0.115
-23.33%
--
--
-0.120
-20%
Estimates Revision
The market is revising Upward the revenue expectations for Applied Therapeutics, Inc. (APLT) for FY2025, with the revenue forecasts being adjusted by 300% over the past three months. During the same period, the stock price has changed by -51.49%.
Revenue Estimates for FY2025
Revise Upward
up Image
+300%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.65%
In Past 3 Month
Stock Price
Go Down
down Image
-51.49%
In Past 3 Month
Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold
Current: 0.230
sliders
Low
1.00
Averages
1.00
High
1.00
Current: 0.230
sliders
Low
1.00
Averages
1.00
High
1.00
Leerink
Outperform -> Market Perform
downgrade
$2 -> $1
2025-12-03
New
Reason
Leerink
Price Target
$2 -> $1
2025-12-03
New
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded Applied Therapeutics to Market Perform from Outperform with a price target of $1, down from $2. With growing concerns over Applied Therapeutics' balance sheet and the likelihood that the company will need to run two additional Phase 3 studies to get govorestat across the goal line, the firm is moving to the sidelines and cutting the stock's rating to Marker Perform.
Leerink
Joseph Schwartz
Outperform
to
Market Perform
downgrade
$1
2025-12-03
New
Reason
Leerink
Joseph Schwartz
Price Target
$1
2025-12-03
New
downgrade
Outperform
to
Market Perform
Reason
Leerink analyst Joseph Schwartz downgraded Applied Therapeutics to Market Perform from Outperform with a $1 price target.
William Blair
Sami Corwin
Buy
to
Hold
Downgrades
n/a
2024-12-23
Reason
William Blair
Sami Corwin
Price Target
n/a
2024-12-23
Downgrades
Buy
to
Hold
Reason
William Blair downgraded Applied Therapeutics to Market Perform from Outperform.
RBC Capital
Brian Abrahams
Hold
Maintains
$4 → $1.5
2024-12-20
Reason
RBC Capital
Brian Abrahams
Price Target
$4 → $1.5
2024-12-20
Maintains
Hold
Reason
RBC Capital analyst Brian Abrahams lowered the firm's price target on Applied Therapeutics to $1.50 from $4 and keeps a Sector Perform rating on the shares. The content of the FDA's recent Warning Letter raises additional questions about data integrity and increases overall risk to the company's govorestat development path across indications, the analyst tells investors in a research note. While there have been some signals of activity for the drug and FDA has pushed for greater flexibility around rare disease approvals, with this added layer of uncertainty, Applied Therapeutics shares may trade more in-line near term, the firm adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Applied Therapeutics Inc (APLT.O) is -0.47, compared to its 5-year average forward P/E of -3.14. For a more detailed relative valuation and DCF analysis to assess Applied Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.14
Current PE
-0.47
Overvalued PE
0.29
Undervalued PE
-6.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.35
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.62
Undervalued EV/EBITDA
-6.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
88.85
Current PS
0.00
Overvalued PS
340.66
Undervalued PS
-162.95
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

APLT News & Events

Events Timeline

(ET)
2025-11-20
07:12:10
Applied Therapeutics to Seek Further Type C Meeting Concerning Govorestat
select
2025-11-20
07:10:56
Applied Therapeutics considers strategic options while cutting workforce by 46%
select
2025-11-13 (ET)
2025-11-13
07:08:08
Applied Therapeutics Announces Departure of Executive Chairman Johnson
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-28NASDAQ.COM
Applied Therapeutics (APLT) Receives Upgrade to Buy: Reasons Behind the Decision

  • Zacks Rank Upgrade: Applied Therapeutics Inc. (APLT) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for APLT has increased by 11.9% over the past three months, reflecting analysts' growing confidence in the company's earnings potential.

  • Investment Strategy: The Zacks rating system, which maintains a balanced distribution of buy and sell ratings, positions APLT in the top 20% of stocks based on earnings estimate revisions, suggesting potential for market-beating returns.

  • Technological Opportunities: The article highlights the intersection of artificial intelligence and quantum computing as a significant investment opportunity, encouraging investors to explore stocks poised to benefit from this technological advancement.

[object Object]
Preview
8.5
11-20Newsfilter
Applied Therapeutics Shares Latest Company Developments

  • Strategic Alternatives Exploration: Applied Therapeutics' Board of Directors is exploring strategic alternatives to maximize shareholder value, which may include mergers, acquisitions, and partnerships, while also reducing the workforce by approximately 46% to conserve cash.

  • Regulatory Developments: The company has completed a Type C meeting with the FDA regarding its lead drug candidate, govorestat, for treating rare diseases, and is evaluating feedback for potential Phase 3 trial designs for both Charcot-Marie-Tooth and Classic Galactosemia.

  • Commitment to Patients: Interim CEO Les Funtleyder emphasized the company's ongoing commitment to advancing govorestat for patients with rare diseases while ensuring shareholder value through strategic reviews.

  • Forward-Looking Statements: The press release includes forward-looking statements that involve risks and uncertainties regarding the company's future operations, strategic plans, and the potential outcomes of their ongoing clinical trials and regulatory processes.

[object Object]
Preview
2.0
11-18NASDAQ.COM
NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress

  • Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.

  • Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.

  • Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.

  • Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Applied Therapeutics Inc (APLT) stock price today?

The current price of APLT is 0.2299 USD — it has increased 9 % in the last trading day.

arrow icon

What is Applied Therapeutics Inc (APLT)'s business?

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).

arrow icon

What is the price predicton of APLT Stock?

Wall Street analysts forecast APLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLT is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Applied Therapeutics Inc (APLT)'s revenue for the last quarter?

Applied Therapeutics Inc revenue for the last quarter amounts to 1,000K USD, increased 719.67 % YoY.

arrow icon

What is Applied Therapeutics Inc (APLT)'s earnings per share (EPS) for the last quarter?

Applied Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -72.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Applied Therapeutics Inc (APLT)'s fundamentals?

The market is revising Upward the revenue expectations for Applied Therapeutics, Inc. (APLT) for FY2025, with the revenue forecasts being adjusted by 300% over the past three months. During the same period, the stock price has changed by -51.49%.
arrow icon

How many employees does Applied Therapeutics Inc (APLT). have?

Applied Therapeutics Inc (APLT) has 35 emplpoyees as of December 05 2025.

arrow icon

What is Applied Therapeutics Inc (APLT) market cap?

Today APLT has the market capitalization of 30.48M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free